HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Researchers Analyze OTC Spray, Powder Products, Finding Possible Respiratory Risks

Executive Summary

Of 32 OTC drug products intended for topical uses but marketed in spray or powder forms – mostly sunscreens and antiperspirants – the powder formulas overall contained larger percentages of particles in the sub-5 µm range capable of penetrating deep into the lungs. The researchers say the study does not reflect agency views or policies but could be useful to FDA in its public health mission.

Advertisement

Related Content

CIR Expert Panel Seeks Proper Balance In Respiratory Exposure Doc, Says Particle Size Isn’t All-Important

Topics

Advertisement
UsernamePublicRestriction

Register

RS139928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel